Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivastigmine in Alzheimer's Disease by BuChE Genotype (RIBA)
NCT02063269Unknown
- Sponsor
- Seoul National University Hospital
- Start
- Feb 2014
- Primary completion
- Jun 2017
- Modality
- Reversible Covalent Inhibitors, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Open-label, single-arm trial of rivastigmine in Alzheimer's disease (AD), sponsored by Seoul National University Hospital. Primary endpoints: Standardized Uptake Values (SUVmean) in PET imaging at 52 weeks and Serum Butyrylcholinesterase activity at 52 weeks. Status: unknown.
02
Drugs
rivastigmine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02063269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02063269.